•  

Posts Tagged: start-up companies

MaRS Innovation featured in International Innovation magazine

MaRS Innovation and its member institutions are is profiled in International Innovation's July issue (#191) in a feature interview with Dr. Rafi Hofstein, MI's president and CEO, written by Rosemary Peters. The article is posted on the publication's website and viewable through a digital interface (pages 80 and 81). Here's an excerpt from Dr. Hofstein's comments: "Canada's academic research community is internationally highly competitive, but it has been argued that its scientific commercial success tags behind other countries such as the U.S. and the ... Read more

Ontario Government Invests $1 Million in Toronto’s Neuroscience Catalyst Consortium

Ministry of Research & Innovation joins founding partners University of Toronto and Janssen Inc., and new partners Evotec AG, MaRS Innovation and Ontario Centres of Excellence, to advance treatments for neurological disorders and develop early-stage biotech companies TORONTO and PHILADELPHIA (June 16, 2015)— Toronto’s neuroscience efforts to find new drugs to treat and manage brain disorders — specifically, mood disorders and Alzheimer's disease — took another step forward as the Government of Ontario’s Ministry of Research and Innovation announced a $1 million ... Read more

ChipCare closes oversubscribed $5 million series A financing

With lead investment from Puffin Partners, the Ontario, Canada-based company is taking lifesaving blood-testing technology to low- and middle-income countries TORONTO, March 3, 2015 — ChipCare Corporation, a University of Toronto start-up company commercializing a handheld, blood-testing platform for HIV and other infectious and non-communicable diseases has closed a $5.045 million Series A financing to bring its first-generation product to market while further developing the platform’s next generation products. The Wall Street Journal's Venture Capital Dispatch blog, Yonge Street Media, BetaKit and PEHub ... Read more

Triphase Accelerator announces new cancer collaboration with Sunnybrook Research Institute

TORONTO and SAN DIEGO (Feb. 26, 2015) — Triphase Accelerator Corporation has entered into an academic center collaboration with Sunnybrook Research Institute (SRI), the research arm of Sunnybrook Health Sciences Centre, a MaRS Innovation member institution. MaRS Innovation is also a Triphase investor. Under the agreement, SRI will assist in the development of Triphase’s novel, first-in-class, fully human bi-specific antibody TRPH 011 and evaluate the role of bifunctional targeting of VEGFR-2 and TIE 2 receptors in cancer. TRPH 011 binds and neutralizes VEGFR-2/KDR ... Read more

UTEST program bends career road for Granata Decision Systems’ founders

TORONTO (January 21, 2015) — MaRS Innovation and the University of Toronto (U of T) are pleased to announce that the founders of Granata Decision Systems Inc., a graduate of the University of Toronto Early-Stage Technology (UTEST) start-up incubator program, have joined Google Inc. This story was covered in TechVibes. Dr. Craig Boutilier is a professor in U of T’s Department of Computer Science. He and Tyler Lu, a graduating PhD student in the same department, co-founded Granata Decision Systems in 2012 to ... Read more

BlueDot, formerly BioDiaspora Inc., secures Series A with Horizons Ventures

Toronto-based commercial arm of BioDiaspora research program tracks global spread of infectious diseases in real-time; fourth MI company to reach Series A TORONTO (Dec. 2, 2014) — BlueDot, a Toronto-based social benefit corporation founded by Dr. Kamran Khan, an infectious disease physician and scientist, tracks and predicts the global spread of infectious diseases. Spun off from St. Michael’s Hospital in partnership with MaRS Innovation (and formerly known as BioDiaspora Inc.), BlueDot, has secured a Series A venture capital funding from Horizons Ventures. Funded ... Read more

UTEST gets a mention in TechVibes piece on Canada’s growing start-up scene

TechVibes gave UTEST, an incubator program jointly run by MaRS Innovation and the University of Toronto, a mention in Laura Leslie's "Canada’s Startup Communities Shining Brighter Than the California Sun," published November 24, 2014, which explores the ecosystem-wide supports in place to encourage entrepreneurship in Canada. Leslie writes: Silicon Valley may be the first place that comes to mind when you think of tech startups, but when considering resources, financial support, and a welcoming atmosphere, Canada has been steadily putting itself on the map. ... Read more

Encycle Therapeutics developing lead molecule to tackle inflammatory bowel disease

Company's collaborative partnership with IRICoR, Université de Montréal and MaRS Innovation, funded by Merck Canada, to advance macrocycle drug TORONTO and MONTREAL, Nov. 10, 2014 — Encycle Therapeutics Inc., a biotechnology start-up founded by Dr. Andrei Yudin of the University of Toronto in partnership with MaRS Innovation, is developing its lead orally-bioavailable macrocycle drug to target integrin a4b7, which is involved in the inflammatory process in a number of diseases, most notably for inflammatory bowel disease. This announcement was covered in SciBX, Drug Discovery ... Read more

BioCentury features Vasomune Therapeutics

Vasomune Therapeutics, a MaRS Innovation start-up company from Sunnybrook Health Sciences Centre's Sunnybrook Research Institute, was featured in a BioCentury emerging company profile by Michael J. Haas. The company is currently raising a Series A financing round and recently closed a seed investment with Genome Canada and an unnamed industry partner. MaRS Innovation also contributed a third of the investment, bringing the round's total to $1.5 million. Haas' profile, "Vasomune: Lassoing Tie2," is available behind a paywall on the BioCentury website. Here's a short ... Read more

MaRS Innovation joins new financing round for AvidBiologics Inc.

TORONTO, Sept. 29, 2014 — AvidBiologics Inc., an oncology drug development company, today announced the closing of a financing round. The company is founded on antibody-drug conjugate (ADC) technologies co-developed with the National Research Council of Canada (NRC). Led by Lumira Capital, the financing round included MaRS Innovation (MI), MaRS Investment Accelerator Fund (IAF), Rosseau Asset Management, and the company's founding investors. This announcement was covered by Dow Jones: Private Equity and Venture Capital and by Canadian Private Equity. Today's financing builds on prior ... Read more
Page 3 of 812345...Last »